Telbivudine for the treatment of chronic hepatitis B

Hepatitis B - telbivudine: review decision - October 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Hepatitis B - telbivudine: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 74 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

Review decision: June 2009 information

A link to the summary of the responses from this consultation.

Appendix 1: Proposal comment summary table (PDF 28 KB)

Review proposal: May 2009 information

A full list of the organisations contacted for this review

Hepatitis B - telbivudine: final appraisal determination 

Hepatitis B - telbivudine: final appraisal determination information

Hepatitis B - telbivudine: final appraisal determination (PDF 94 KB)

Consultee and commentator comments on the ACD

Southampton Health Technology Assessment Group

Southampton Health Technology Assessment Group (PDF 15 KB)

Department of Health

Department of Health (PDF 12 KB)

Bury Primary Care Trust

Bury Primary Care Trust (PDF 12 KB)

Royal College of Physicians

Royal College of Physicians (PDF 27 KB)

Royal College of Nursing

Royal College of Nursing (PDF 19 KB)

British Infection Society

British Infection Society (PDF 17 KB)

Novartis Pharmaceuticals - appendix A

Novartis Pharmaceuticals - appendix A (PDF 526 KB)

Novartis Pharmaceuticals

Novartis Pharmaceuticals (PDF 201 KB)

Expert comments on the ACD

Ms Penny Wilson Webb

Ms Penny Wilson Webb (PDF 45 KB)

Professor Howard Thomas

Professor Howard Thomas (PDF 15 KB)

Table of comments on the ACD

Hepatitis B - telbivudine: Appraisal consultation document 

Evaluation report

Non-manufacturer submissions

Royal College of Physicians

Royal College of Physicians (PDF 90 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 38 KB)

Novartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd (PDF 567 KB)

Expert written personal statements

Wilson Webb

Wilson Webb (PDF 39 KB)

Thomas

Thomas (PDF 35 KB)

Dusheiko

Dusheiko (PDF 41 KB)

Boxall

Boxall (PDF 36 KB)

Hepatitis B - telbivudine: evidence review group report

Hepatitis B - telbivudine: evidence review group report (PDF 1.11 MB)

Pre-meeting briefing

Pre-meeting briefing (PDF 162 KB)

Stakeholder list: final matrix

Draft scope pre referral

Provisional matrix pre referral

Comments on the matrix

Comments on the scope

Final scope